Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarrhea and the Treatment of Clostridium difficile Disease

Lynne V. McFarland, Ph.D.1,2
1Department of Health Services Research and Development, Veterans Administration Puget Sound Health Care System, Seattle, Washington, and 2Department of Medicinal Chemistry, University of Washington, Seattle, Washington

CONTEXT: Antibiotic-associated diarrhea (AAD) is a common complication of most antibiotics and Clostridium difficile disease (CDD), which also is incited by antibiotics, is a leading cause of nosocomial outbreaks of diarrhea and colitis. The use of probiotics for these two related diseases remains controversial.

OBJECTIVE: To compare the efficacy of probiotics for the prevention of AAD and the treatment of CDD based on the published randomized, controlled clinical trials.

DATA SOURCES: PubMed, Medline, Google Scholar, NIH registry of clinical trials, metaRegister, and Cochrane Central Register of Controlled Trials were searched from 1977 to 2005, unrestricted by language. Secondary searches of reference lists, authors, reviews, commentaries, associated diseases, books, and meeting abstracts.

STUDY SELECTION: Trials were included in which specific probiotics given to either prevent or treat the diseases of interest. Trials were required to be randomized, controlled, blinded efficacy trials in humans published in peer-reviewed journals. Trials that were excluded were pre-clinical, safety, Phase 1 studies in volunteers, reviews, duplicate reports, trials of unspecified probiotics, trials of prebiotics, not the disease being studied, or inconsistent outcome measures. Thirty-one of 180 screened studies (totally 3,164 subjects) met the inclusion and exclusion criteria.

DATA EXTRACTION: One reviewer identified studies and abstracted data on sample size, population characteristics, treatments, and outcomes.

DATA SYNTHESIS: From 25 randomized controlled trials (RCTs), probiotics significantly reduced the relative risk of AAD (RR = 0.43, 95% CI 0.31, 0.58, p < 0.001). From six randomized trials, probiotics had significant efficacy for CDD (RR = 0.59, 95% CI 0.41, 0.85, p = 0.005).

CONCLUSION: A variety of different types of probiotics show promise as effective therapies for these two diseases. Using meta-analyses, three types of probiotics (Saccharomyces boulardii, Lactobacillus rhamnosus GG, and probiotic mixtures) significantly reduced the development of antibiotic-associated diarrhea. Only S. boulardii was effective for CDD.

(Am J Gastroenterol 2006;101:812–822)

Antibiotic-associated diarrhea (AAD) is a common complication of antibiotic use. The frequency of AAD can be high (26–60%) during hospital outbreaks or moderate (13–29%) during endemic periods and is relatively infrequent in outpatient settings (<0.1%) (1–3). Risk factors for AAD include broad-spectrum antibiotics, host factors (age, health status, gender), hospitalization status, and exposure to nosocomial pathogens (2, 4). AAD usually occurs 2–8 wk after exposure to antibiotics as a result of disrupting intestinal microflora. One of the roles of intestinal microflora is to act as a protective barrier that resists the colonization of intestinal pathogens (5). Without this protective barrier, patients are susceptible to infection by opportunistic pathogens.

Hospitalized patients exposed to antibiotics may develop Clostridium difficile disease (CDD). Recently, this pathogen caused nosocomial outbreaks in Canadian hospitals that resulted in over 100 deaths (6). Consequences of AAD and CDD include extended hospital stays (3–7 days), increased rates of subsequent infections (20–65%), higher hospital costs (up to $1 billion/yr) and 2–3 times increased rates of mortality (7–11).

Current therapies for AAD are lacking. Strategies to date include discontinuing the inciting antibiotic, restricting the
use of high-risk antibiotics and specific antibiotic treatments if the etiology is known. For CDD, 80% respond well to the initial treatment of vancomycin or metronidazole. The remaining 20% may develop subsequent episodes of CDD, which may persist over several years, despite repeated antibiotic treatments (9).

Probiotic therapy is well suited to these two types of microbial induced diseases. Probiotics assist in reestablishing the disrupted intestinal microflora, enhancing immune responses and clearing pathogens and their toxins from the host (12–14). Research using probiotics has been reported for the past 28 yr, but the studies have been variable in trial design, type of probiotic, had differing doses and durations of treatment, and thus have yielded contradictory results. The lack of definitive evidence regarding efficacy and safety is limiting the use of this type of treatment strategy. There is a growing interest in probiotics for the treatment of AAD and CDD due to the wide availability of probiotics as dietary supplements and the concern over recent outbreaks of severe CDD in Canada and the United Kingdom (6, 15). Two meta-analyses done in 2002 presented results on only 11 trials and failed to discuss possible reasons for the conflicting findings and did not present detailed study information (16, 17). A recent Cochrane review on treatments for CDD did not include probiotics (18). The need for a meta-analysis of probiotics for these two antibiotic associated diseases is apparent.

METHODS

Objectives
The objectives of this meta-analysis are to assess the efficacy and safety of probiotics for (i) the prevention of AAD and (ii) the treatment of CDD.

Criteria for Study Selection
Abstracts of all citations and retrieved studies were reviewed and rated for inclusion. Full articles were retrieved if specific treatments were given to either prevent or treat the disease of interest. Inclusion criteria include randomized, controlled, blinded efficacy trials in humans published in peer-reviewed journals. Exclusion criteria include pre-clinical studies, case reports or case series, Phase 1 safety studies in volunteers, reviews, duplicate reports, trials of unspecified probiotics, trials of prebiotics, not the disease being studied, or inconsistent outcome measures. External and internal validity is strengthened by including only randomized controlled trials (RCTs).

Outcomes and Definitions
The primary outcome for AAD is defined as diarrhea (≥3 loose stools/day for at least 2 days or ≥5 loose stools/48 h) within 2 months of antibiotic exposure (2, 11). The primary outcome of CDD is defined as a new episode of C. difficile positive diarrhea within 1 month of a previous CDD episode (19). Documentation of diarrhea is based on clinical assessment and self-report of symptoms by daily symptom diaries.

Data Sources
PubMed, Medline, and Google Scholar were searched from 1977 to 2005 for articles unrestricted by language. Non-English articles were translated. Three on-line clinical trial registers were searched: Cochrane Central Register of Controlled Trials (http://www.cochrane.org), metaRegister of Controlled Trials (http://www.controlled-trials.com/mrct) and National Institutes of Health (http://www.clinicaltrials.gov). Secondary and hand searches of reference lists, authors, reviews, commentaries, associated diseases, books, and meeting abstracts were also performed. Six search terms for RCTs (RCT, human, blinding, Phase 2, Phase 3, efficacy) were combined with 15 terms for probiotics. Search terms included probiotics, microflora, antibiotics, Clostridium difficile, colitis, PMC, diarrhea, Saccharomyces, Lactobacilli, Bifidobacteria, Enterococci, Bacilli, VSL#3, symbiotics, and Lactinex. Search strategies were broad-based initially, then narrowed to the disease of interest (20). The procedure for this meta-analysis was designed as suggested by Egger et al. and MOOSE guidelines using clearly delineated parameters, a priori inclusion and exclusion criteria, and standardized data extraction methods (21–23).

Data Extraction
Information on study design, methods, interventions, outcomes, adverse effects, and treatments was extracted from each article. Data on patient inclusion and exclusion criteria, number of completed subjects, attrition, treatment dose and duration, and outcome was extracted into a standardized table. In some cases, the primary or secondary author was contacted for data not reported in the original article. The data abstraction was completed individually, but verified using historic searches with two other researchers for previous review articles (24, 25). A few trials had multiple probiotic arms with a common control group. Each probiotic arm and control group was analyzed separately.

Assessment of Methodological Quality
Studies that met the inclusion criteria were graded for quality using a scale reported by the U.S. Preventive Services Task Force (26). Quality of evidence is rated from 1 to 3 (poor, fair, and good) based on randomization, study design, sample size, generalizability, study biases, and outcome assessment. Study quality was not integrated with the model weights, as trials of poor quality were excluded from review and this practice is not uniformly recommended (27). Weights for this analysis are based solely on sample sizes.

Statistical Analysis
Statistical analysis was performed using Stata software version 8.0 (Stata Corporation, College Station, TX). Relative
risks with 95% confidence intervals were computed as summary statistics. Heterogeneity across trials was evaluated using the Mantel-Haenszel method. If the studies were homogeneous, a fixed-effects model was used and a pooled relative risk was calculated with the Mantel-Haenszel method. If the studies were heterogeneous a random effect was employed and a pooled relative risk was calculated using the DerSimonian and Laird method. When heterogeneity was detected, a subgroup analysis was conducted. A priori subgroups were by type of probiotic, dose and indication (AAD or CDD). A funnel plot as well as an adjusted rank correlation test using the Begg and Mazumdar method were used to assess publication bias.

### Excluded Studies
AAD. Of the AAD studies, 79 failed to meet one or more of the inclusion criteria. Most were reviews or commentaries (n = 57), pre-clinical or Phase 1 safety studies done in healthy volunteers (n = 11) or had no control group (n = 4). AAD was a post hoc outcome in three trials and one study failed to provide outcome data. Some studies were excluded because the type of probiotic was not specified (31, 32) or only a prebiotic (oligosaccharide with no living probiotic) was given as the intervention (33).

CDD. Of the CDD studies, 70 failed to meet one or more of the inclusion criteria. Most were reviews or commentaries (n = 41), pre-clinical or Phase 1 safety studies done in healthy volunteers (n = 7) or had no control group (n = 18). Some studies were excluded because CDD was a post hoc outcome (n = 3) or only a prebiotic (oligosaccharide with no living probiotic) was given as the intervention (34).

### Efficacy Studies
AAD. Twenty-five RCTs provided adequate data regarding efficacy in a total of 2,810 patients with AAD, as shown in Table 1. Of the 25 trials, 13 (52%) reported a significant reduction of AAD in the probiotic-treated group compared with the placebo group in their study. Twelve studies did not reject the null hypothesis of no difference in the incidence of AAD for probiotic treated versus controls.

These contradictory results may be due to differences in the study population enrolled, the type of probiotic, the dose of probiotic given, or the duration of treatment. Typically, these trials were done in adults given broad-spectrum antibiotics (64%), while 36% of the trials were done in children taking antibiotics. Of 16 RCTs of AAD in adult patients, 7 (44%) showed significant efficacy for probiotics. Of nine RCTs of AAD in children, six (67%) had significant efficacy. There was not a significant difference in efficacy of probiotics according to whether adults or children were enrolled (Fisher’s p = 0.41). The types of probiotics varied from single strains (Saccharomyces boulardii, Lactobacillus rhamnosus GG, Bifidobacterium longum, Clostridium butyricum miyairi, Lactobacillus acidophilus, Enterococcus faecium SF68), to mixtures of two types of probiotic and to a symbiotic (a probiotic combined with a pre-biotic substance). Daily doses of probiotics ranged from $1 \times 10^6$ to $1 \times 10^{11}$, with a mean of $3 \times 10^9$. Use of a high dose ($\geq 10^{10}$/day) of
## Table 1. Description of 25 Randomized Controlled Trials of Probiotics for the Prevention of Antibiotic Associated Diarrhea

| N     | Subjects                                           | Probiotic-Treated | Control Group |
|-------|----------------------------------------------------|-------------------|---------------|
| 388   | Adults, b-lactam or tetracycline                   | SB $4 \times 10^9$ | 9 (4.5)       |
| 180   | Adults, varied                                     | SB $2 \times 10^{10}$ | 11 (9.5)      |
| 193   | Adults, b-lactams                                  | SB $2 \times 10^{10}$ | 7 (7.2)       |
| 246   | Peds, varied                                       | SB $1 \times 10^{10}$ | 4 (3.4)       |
| 69    | Elderly, varied                                    | SB $4 \times 10^9$ | 7 (21)        |
| 43    | *H. pylori* + 3 abx                               | SB $5 \times 10^9$ | 1 (5)         |
| 119   | Peds, varied                                       | LGG $4 \times 10^{10}$ | 3 (5)         |
| 188   | Outpatient peds, varied oral abx                   | LGG $1-2 \times 10^{10}$ | 7 (7.5)      |
| 81    | Hosp peds, varied                                  | LGG $1 \times 10^{10}$ | 3 (6.7)       |
| 267   | Hosp adults 70% b-lactam/varied                    | LGG $2 \times 10^{10}$ | 39 (29.3)     |
| 42    | *H. pylori* + 3 abx                               | LGG $6 \times 10^9$ | 1 (5)         |
| 120   | *H. pylori* + 3 abx                               | LGG $1 \times 10^{10}$ | 2 (3.4)       |
| 100   | *H. pylori* + 3 abx                               | BC $6 \times 10^9$ | 15 (30)       |
| 20    | Adults, clindamycin                                | BL $5 \times 10^{10}$ | 4 (40)        |
| 110   | Peds, varied                                       | CB $1-4 \times 10^7$ | 6 (7)         |
| 45    | Adults, varied                                     | EF $1.5 \times 10^7$ | 2 (8.7)       |
| 200   | Adults with TB                                     | EF $8 \times 10^8$ | 5 (5)         |
| 27    | Adults amoxicillin                                 | LA $1.2 \times 10^8$ | Varied 0      |
| 79    | Hosp adults, ampicillin                            | Lactinex $2 \times 10^9$ | 3 (8.3)      |
| 38    | Peds, amoxicillin                                  | Lactinex $2 \times 10^9$ | 10 (66)       |
| 20    | Adults, clindamycin                                | LABLa $1 \times 10^{11}$ | 2 (20)        |
| 42    | *H. pylori* + 3 abx                               | LABL $5 \times 10^9$ | 1 (5)         |
| 77    | Children, varied                                   | BLST $1 \times 10^7$ | 6 (16)        |
| 98    | Children, varied                                   | LS FOS $5.5 \times 10^9 + 250$ | 14 (29)     |
| 18    | Infants 1–36 months on antibiotics                 | LABI $6 \times 10^9$ | 3 (37.5)      |

**N** = number of subjects with evaluable outcome; **SB** = *Saccharomyces boulardii*; **LGG** = *Lactobacillus rhamnosus* GG; **BC** = *Bacillus clausii*; **BL** = *Bifidobacterium longum*; **CB** = *Clostridium butyricum* Miyairi; **EF** = *Enterococcus faecium* SF68; **LA** = *Lactobacillus acidophilus*; **LALB** = Lactinex *L. acidophilus* and *L. bulgaricus*; **LABL** = *Lactobacillus acidophilus* and *Bifidobacterium longum*; **LABLa** = *Lactobacillus acidophilus* and *Bifidobacterium lactis*; **BLST** = *Bifidobacterium lactis* and *Streptococcus thermophilus*; **LSFOS** = *Lactobacillus sp* and fructo-oligosaccharide; **LABI** = *Lactobacillus acidophilus* and *Bifidobacterium infantis*; **Txt** = treatment; **Abx** = antibiotic.

Quality: 1 = poor; 2 = fair; 3 = good (26).

*Any gastrointestinal complaint including diarrhea.
Lactobacillus rhamnosus GG (60). No cases of bacteremia or fungemia or other serious adverse events were reported in the 31 RCTs.

PROBIOTIC EFFICACY

A probiotic was associated with a significant efficacy for AAD. Eight (67%) of 12 RCTs with a positive efficacy for AAD used a high daily dose of probiotic compared with only 2 (17%) of 12 RCTs that showed no significant difference yet used a high daily dose (p = 0.04). The duration of probiotic treatment also varied widely from 5 days to 8 wk (median of 2 wk), but the duration of probiotic did not significantly differ in trials showing protective efficacy compared to no difference.

Table 2. Meta-Analyses of Relative Risks Stratified by Type of Probiotic for the Prevention of Antibiotic Associated Diarrhea

| Probiotic                        | Number of RCT | Combined RR | 95% CI     | p Value | Type of Model | References |
|----------------------------------|---------------|-------------|------------|---------|---------------|------------|
| Saccharomyces boulardii          | 6             | 0.37        | 0.26, 0.52 | <0.0001 | Fixed         | (35–40)    |
| Lactobacillus rhamnosus GG       | 6             | 0.31        | 0.13, 0.72 | 0.006   | Random        | (41–45)    |
| Single strains of probiotics     | 6             | 0.46        | 0.21, 1.03 | 0.06    | Random        | (46–51)    |
| Mixtures of two probiotics       | 7             | 0.51        | 0.38, 0.68 | <0.0001 | Fixed         | (40, 47, 52–56) |

Single strains included: Clostridium butyricum MIYAIRI; Enterococcus faecium SF68; Lactobacillus acidophilus; Bifidobacterium longum; Bacillus clausii; Bifidobacterium lactis; Streptococcus thermophilus; or Lactobacillus sporogenes.

Mixtures included: Lactis = L. acidophilus and L. bulgaricus; Lactobacillus acidophilus and Bifidobacterium lactis; Lactobacillus acidophilus and Bifidobacterium infantis. p Value for null hypothesis that RR = 1.

Some contradictory results may be due to differences in the study population enrolled, the type of probiotic, the dose of probiotic given or the duration of treatment. All these trials were done in adults with prior antibiotic exposure and three studies were done exclusively in patients with recurrent CDD. The types of probiotics included S. boulardii, L. rhamnosus GG, L. plantarum 299v; and a mixture of L. acidophilus and Bifidobacterium bifidum. Five of the six RCTs were treating patients with established CDD and the probiotic was combined with standard antibiotics (either vancomycin or metronidazole) for treating CDD. Unfortunately, the type or dose of the antibiotic was not randomized along with the probiotic arm for any of the studies. Daily doses of probiotics ranged from $2 \times 10^{10}$ to $6 \times 10^{11}$, with a mean daily dose of $5 \times 10^{9}$. The duration of probiotic treatment also varied from 3 to 5 wk, with a median of 3 wk. The number of trials was too small to determine if a dose-response or duration-response effect was present.

DATA FROM 25 RCTS WERE COMBINABLE FOR A META-ANALYSIS, as they reported frequencies of outcome in treated and controls (35–56). As the $\chi^2$ test for heterogeneity was 82.5 ($p < 0.001$), indicating a low degree of homogeneity between studies, a random-effects model was utilized. The combined efficacy shows probiotics have a significant protective effect for AAD (Fig. 2). The relative risk for AAD was 0.43 (95% CI 0.31, 0.58), z = 5.4, p < 0.001. A funnel plot (Fig. 3) may indicate the modest presence of some publication bias or may reflect the differences due to the type of probiotic. No significant evidence of publication bias was found using the Begg rank correlation test ($z = -1.05$, $p = 0.29$).

As the efficacy may vary by the probiotic strain being tested, additional meta-analyses were done, stratified a priori by the probiotic type. Two single probiotic strains showed significant efficacy for AAD: S. boulardii and L. rhamnosus GG (Table 2), as well as mixtures composed of two different types of probiotics. The meta-analysis for other single probiotic strain preparations than those above was not significantly protective for AAD, but as the strains were diverse, clinical conclusions should be made with caution.

CDD. Six RCTs provided adequate data regarding efficacy in a total of 354 patients with CDD, as shown in Table 3 (57–62). Of the six trials, two (33%) reported a significant reduction of CDD recurrences in the probiotic-treated group compared with the placebo group. Four studies did not reject the null hypothesis of no difference in the incidence of CDD recurrences for probiotic treated versus control treated groups. These contradictory results may be due to differences in the study population enrolled, the type of probiotic, the dose of probiotic given or the duration of treatment. All these trials were done in adults with prior antibiotic exposure and three studies were done exclusively in patients with recurrent CDD. The types of probiotics included S. boulardii, L. rhamnosus GG, L. plantarum 299v, and a mixture of L. acidophilus and Bifidobacterium bifidum. Five of the six RCTs were treating patients with established CDD and the probiotic was combined with standard antibiotics (either vancomycin or metronidazole) for treating CDD. Unfortunately, the type or dose of the antibiotic was not randomized along with the probiotic arm for any of the studies. Daily doses of probiotics ranged from $2 \times 10^{10}$ to $6 \times 10^{11}$, with a mean daily dose of $5 \times 10^{9}$. The duration of probiotic treatment also varied from 3 to 5 wk, with a median of 3 wk. The number of trials was too small to determine if a dose-response or duration-response effect was present.

Data from six RCTs were combinable for a meta-analysis, as they reported frequencies of outcome in treated and controls. As the $\chi^2$ test for heterogeneity was 4.6 ($p = 0.5$), indicating a high degree of homogeneity between studies, a fixed-effects model was utilized. The combined efficacy shows probiotics have a significant protective effect for CDD (Fig. 4). The relative risk for CDD was 0.59 (95% CI 0.41, 0.85), z = 2.8, p = 0.005. A funnel plot (Fig. 5) indicates the absence of publication bias. No significant evidence of publication bias was found using the Begg rank correlation test ($z = 0.56$, $p = 0.57$).

Of the three different probiotics tested for the treatment of CDD, only S. boulardii showed significant reductions in recurrences of CDD (57, 58). L. rhamnosus GG and L. plantarum 299v did not show significant differences in CDD recurrence rates in probiotic versus control treated groups. One trial testing a probiotic mixture (L. acidophilus and B. bifidum) for the prevention of CDD did not show significant efficacy (62).

ADVERSE EVENTS

Twenty-six (84%) of the 31 trials presented data on adverse reactions, but five trials did not (35, 48, 52, 60, 62). In 24 trials, no adverse reactions were associated with the probiotic treatments. McFarland et al. reported significantly more subjects taking S. boulardii reported thirst (9%) or constipation (14%) compared with controls (57). Wullt et al. reported mild bloating (25%) or gas (37%) was associated with L. rhamnosus GG (60). No cases of bacteremia or fungemia or other serious adverse events were reported in the 31 RCTs.

COMMENT

Antibiotic-induced diseases present unique treatment challenges for the health-care provider. Treatment with additional
Table 3. Description of Six RCT of Probiotics for the Treatment or Prevention of *Clostridium difficile* Disease

| Probiotic-Treated Control Group | Total Subjects | N Subjects | Probiotic Per Day | Antibiotic Dose | Duration Follow-Up | Total Cured | No. Failed | Antibiotic Dose | Total Cured | No. Failed | Quality Weight Reference |
|---------------------------------|----------------|------------|------------------|-----------------|-------------------|-------------|------------|----------------|-------------|------------|-------------------------|
| Adult CDD/RCDD SB + V/M         | 124            | 111        | 2 × 10^11        | 4 weeks         | 4 weeks           | 15 (26)    | 42         | 30 (44.8)     | 37          | 3         | 3 (16.7)                |
| Adult RCDD SB + V2 × 10^10      | 32             | 28         | 2 g              | 4 weeks         | 4 weeks           | 3 (16.7)   | 15         | 7 (50)         | 7           | 2         | 2 (66.7)                |
| Adult CDD/RCDD LGG + V or M    | 25             | 21         | nr               | nr              | nr                | 3 (36.4)   | 7          | 5 (36.4)      | 9           | 2         | 2 (66.7)                |
| Adult RCDD LP 299v M5 × 10^10   | 20             | 16         | nr               | 38 days         | None              | 3 (37.5)   | 7          | 1 (14.3)      | 6           | 2         | 2 (66.7)                |
| Adult RCDD LGG Vo or M 6 × 10^11| 15             | 12         | Varied           | 3 wk            | 4 wk              | 3 (37.5)   | 5          | 1 (14.3)      | 6           | 2         | 2 (66.7)                |
| Inpatients varied antibiotics V or M | 138         | 130        | nr               | 20 days         | None              | 3 (37.5)   | 6          | 1 (14.3)      | 6           | 2         | 2 (66.7)                |

N = number of subjects with evaluable outcome; SB = *Saccharomyces boulardii*; LGG = *Lactobacillus rhamnosus* GG; LP = *Lactobacillus plantarum* 299v; V = metronidazole; nr = not reported; LABB = *Lactobacillus acidophilus* and *Bifidobacterium bifidum*; Quality: 1 = poor; 2 = fair; 3 = good (26).

Antibiotics for diarrhea symptoms can worsen the condition by further disrupting the intestinal microflora. Efforts to prevent AAD by restricting antibiotic use in hospitals or reducing inappropriate antibiotic prescriptions has met with only limited success (63–65). Probiotics have shown promise in antibiotic mediated diseases as they are not disruptive of intestinal microflora and have multiple mechanisms of action in which to combat opportunistic pathogens *in situ* (12, 24). Acceptance of probiotics in routine formularies has been slow due to the lack of a consensus on the efficacy and safety of probiotics.

The result of the literature search on probiotics found that the majority of articles (54%) screened for inclusion were reviews or commentaries. Unfortunately, the prevalence of RCTs is not frequent in this area. Only 31 (17%) were included in this meta-analysis. This is the largest number of RCT analyzed by meta-analysis to date.

In this meta-analysis of 31 randomized, controlled trials, a clear message is seen supporting the use of probiotics for two antibiotic-associated diseases. Probiotics given for the prevention of AAD have a pooled relative risk of 0.43 (0.31, 0.58), using a random-effects model. This is similar to pooled estimates of risk from three earlier meta-analysis based on fewer (5–9) RCTs (16, 17, 66). D’Souza et al. pooled nine trials and found probiotics significantly reduced the odds of AAD (OR = 0.37, 95% CI 0.26, 0.52), but did not provide data on heterogeneity testing or publication bias (16). Cremonini et al. analyzed seven trials and found a pooled relative risk of 0.40 (95% CI 0.27, 0.57) (17). Although it was not stated if this was a random- or fixed-effects model, no significant heterogeneity was found (p = 0.42) and no publication bias was seen in a funnel plot. Publication bias was not assessed by either Begg’s or Egger’s test in this meta-analysis. Szajewska and Mrukowicz analyzed five trials and found a pooled relative risk of 0.43 (95% CI 0.23, 0.78) using a random-effects model (66). No significant publication bias was found. However, this meta-analysis was restricted to one type of probiotic (*S. boulardii*) and did not examine other types of probiotics. These three meta-analyses were small and did not consistently provide full information on heterogeneity and publication bias. Despite these limitations, the three meta-analyses demonstrated a significant efficacy of probiotics for the prevention of AAD and validated our findings.

The current meta-analysis included a large number of RCTs and fully described potential biases.

The etiologies of AAD are diverse and largely not identified. Approximately one-third of AAD is due to *C. difficile*, while another 10–20% is due to bacterial and viral etiologies (2). Of the 25 RCTs in this analysis, only 9 (36%) attempted to determine the etiologies of AAD in their trials. Only four trials reported treatment-specific efficacies stratified on *C. difficile* status and none were significant (36–38, 43). This is not surprising, as the original trials were powered for AAD and not *C. difficile* AAD. As the proportion of *C. difficile* is variable and may only account for one-third of the enrolled patients, trials for the prevention of *C. difficile* AAD typically
Figure 2. Forest Plot of 25 randomized controlled trials of probiotics for the prevention of antibiotic associated diarrhea showing crude and pooled risk ratios. SB = *Saccharomyces boulardii*; LGG = *Lactobacillus rhamnosus* GG; BC = *Bacillus clausii*; BL = *Bifidobacterium longum*; CB = *Clostridium butyricum* MIYAIRI; EF = *Enterococcus faecium* SF68; LA = *Lactobacillus acidophilus*; LALB = Lactinex = *L. acidophilus* and *L. bulgaricus*; LABL = *Lactobacillus acidophilus* and *Bi* *fi* *dobacterium longum*; LABLa = *Lactobacillus acidophilus* and *Bi* *fi* *dobacterium lactis*; BLST = *Bifidobacterium lactis* and *Streptococcus thermophilus*; LSFOS = *Lactobacillus sporogenes* and fructo-oligosaccharide; LABI = *Lactobacillus acidophilus* and *Bifidobacterium infantis*.

have not been done due to the large sample sizes required. As an alternative, probiotic treatment trials for patients with existing CDD have usually been done. Of the six RCTs, five were for treatment and only one was for the prevention of CDD. The pooled relative risk from this meta-analysis for CDD was 0.59 (0.41, 0.85). As no significant heterogeneity was found ($p = 0.5$) even for this limited number of trials, a fixed effect model was used. Both a funnel plot and Begg’s test did not find significant publication bias ($p = 0.57$). The CDD meta-analysis relies heavily upon two studies done by the author, but the potential for bias has been limited by including only trials published in peer-reviewed journals and by the use of quantitative outcomes. The trials were weighted by study size and not a qualitative measure of quality, which has the potential for bias, especially if the author is evaluating their own studies. We did not find any other meta-analyses of probiotics for CDD for comparison. There are also too few trials in the literature to analyze the efficacy of probiotics for carriers versus diseased patients or by the history of the patient (initial cases compared to recurrent CDD), although these types of trials would be useful.

The most frequent limitation of these RCTs was that studies may have suffered from insufficient power to detect a significant difference. Few studies reported sample size calculations in their methods section and three authors reported that slow recruitment caused premature termination of the trial (56, 59, 62). Calculating a mean sample size based on a 50% reduction of AAD for probiotic treated versus 37% AAD in controls (mean taken from 25 AAD trials) with an alpha of 0.05 and a power of 80%, the required number of patients would be 204 per trial. Few (3, 10%) of the 31 RCTs reached this enrollment goal. Future trials need to calculate required sample sizes before initiating the study and strive to recruit sufficient numbers of patients.
Heterogeneity between studies can be a limiting factor for meta-analyses. It may arise from differences in study populations, type of probiotic being investigated or differences in probiotic doses and duration of treatment. For AAD trials, the heterogeneity may be due to the different populations enrolled, as both adults and children given a variety of different types of antibiotics were studied. However, the efficacy was not found to differ for adult and pediatric subjects. For RCT involving CDD, all trials enrolled adults exposed to antibiotics.

Another source of heterogeneity for probiotic trials is the type of probiotic itself. Significant differences in effectiveness have been reported for different species and strains of similar species of bacteria and yeasts (24, 67, 68). Unfortunately, many trials only report the genus and species and do not provide strain designations. A few studies (excluded from the analysis) even failed to provide the identity of the probiotic and only stated the treatment was “living yogurt” or “protective lactobacilli.” Future studies need to provide the complete identity of the probiotic being tested.

Trials for AAD failing to show significant efficacy may have used sub-therapeutic doses of probiotics (<10^10 organisms/day) or failed to provide the probiotic during the entire period of susceptibility when normal intestinal microflora is becoming reestablished (usually 6–8 wk) (2). This meta-analysis found a dose-response for probiotics used to prevent AAD. Trials for the treatment of CDD were more homogeneous in terms of probiotic treatments than trials for AAD. Probiotic doses and durations were similar (100% of those reporting doses used >10^10/day) and all studies treated patients for at least 3 wk.

Another limitation in these trials was the lack of standardization when a combination treatment regimen was used. The common strategy for treating CDD infections is to combine the investigational probiotic with one of the standard antibiotics (vancomycin or metronidazole) given to treat C. difficile. The hypothesis of the combination therapy is that the antibiotic kills vegetative C. difficile organisms in the intestine, which would clear the pathogenic toxins, and the probiotic would assist in reestablishing the protective intestinal microflora so that when residual spores germinate, colonization is rebuffed by the newly restored microflora barrier. Unfortunately, only the probiotic component of these trials was randomized. The standard antibiotic varied by type and dose and was not controlled in most trials. This is an important consideration because Surawicz et al. found only a high dose of vancomycin (2 g/day) completely cleared C. difficile toxins by the end of 10 days of therapy, whereas a lower dose (500 mg/day) of vancomycin failed to clear toxins in 10% and metronidazole (1.5 g/day) only cleared toxins in 40% of the patients (58). Future studies should randomize the combination treatment with a standard dose of both the
standard antibiotic and the probiotic to test the complete regimen.

Potential biases in review process may be due to publication bias. Sutton et al. reviewed 48 meta-analyses and found 30 (63%) made no reference to publication bias or reported funnel plots (69). In this meta-analysis, publication bias was minimized by conducting extensive searches through multiple databases and receiving original data from the authors. Funnel plots for AAD and CDD showed there may be some publication bias present for AAD, but the discovery of numerous negative trials for AAD may have minimized this bias. Selection and ascertainment bias was minimized by including only RCTs with validated outcomes.

Concerns about the safety of probiotics have been raised. As probiotics are living organisms given to ill patients, the potential for adverse reactions exists. Some intestinal bacteria have been shown to translocate from the intestine to other organs and antibiotic-resistance gene acquisition also is a potential concern. These two problems have yet to be observed in clinical trials using probiotics. Although case reports and case series of bacteremia and fungemia have been reported in the literature, no incidents occurred in patients enrolled in the 31 RCTs reviewed for this meta-analysis (70, 71). Caution should be exercised for patients who are severely ill and receiving nutrition or antibiotics through a potentially open portal (catheter or nasogastric tube). Infrequent blood-stream infections have been reported, most probably due to contamination of the environment as the probiotic capsule is opened at bedside and mixed with food (72). Rare complications including endocarditis and liver abscesses have been associated with L. rhamnosus use (73, 74). Bacteremia and fungemia have been associated with probiotics, but respond well to antibiotics or anti-fungal medications (75–78).

Considering that millions of doses of probiotics are taken per year globally, the risk of complications due to probiotics is extremely low. However, prolonged safety issues have not been addressed in studies.

CONCLUSION

In summary, the present meta-analyses suggest that probiotics can significantly reduce the incidence of AAD and are an effective treatment for CDD. Future studies should expand the types of probiotics tested and pay careful attention to proper study design and sample size considerations.

ACKNOWLEDGMENT

The author had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The author also would like to acknowledge the participants in these trials; without their willingness to volunteer, scientific discoveries would not be made.

STUDY HIGHLIGHTS

What Is Current Knowledge

- Treatment strategies for diseases that involve the disruption of intestinal microflora by antibiotics may be particularly effective when probiotics are used.
- Studies of the efficacy of probiotics in C. difficile colitis are conflicting and a consensus has yet to be reached.

What Is New Here

- This meta-analysis pooled together 31 randomized controlled trials to determine if probiotics are efficacious overall for these types of diseases.
- Three different probiotics (Saccharomyces boulardii, Lactobacillus rhamnosus GG and probiotic mixtures) helped prevent antibiotic-associated diarrhea but only S. boulardii appeared useful for Clostridium difficile disease.

REFERENCES

1. Levy DG, Stergachis A, McFarland LV, et al. Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin Ther 2000;22:91–102.
2. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 1998;16:292–307.
3. Winston DJ, Ho WG, Bruckner DA, et al. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, cefazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991;115:849–59.
4. Ackermann G, Thomalla S, Achermann F, et al. Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhea. J Med Microbiol 2005;54(Pt 2):149–53.
5. McFarland LV. Normal flora: Diversity and functions. Microb Ecol Health Dis 2000;12:193–207.
6. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. J Ayub Med Coll Abbottabad 2004;17:466–72.
7. Al-Eidan, McElvay JC, Schott MG, et al. Clostridium difficile-associated diarrhea in hospitalized patients. J Clin Pharm Ther 2000;25:101–9.
8. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346–53.
9. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: Epidemiology and clinical
characteristics. Infect Control Hosp Epidemiol 1999;20:43–50.
10. Miller MA, Hyland M, Ofner-Agostini M, et al, Canadian Hospital Epidemiology Committee. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002;23:137–40.
11. Oldfield EC. Clostridium difficile-associated diarrhea: Risk factors, diagnostic methods and treatment. Rev Gastroenterol Disord 2004;4(4):186–95.
12. McFarland LV. A review of the evidence of health claims for biotherapeutic agents. Micro Ecol Health Dis 2000;12:65–76.
13. Qamar A, Aboudula S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001;69:2762–5.
14. Elmer GW. Probiotics: “Living drugs.” Am J Health Syst Pharm 2001;58:1101–9.
15. Katikireddi V. UK launches inquired into Clostridium difficile outbreak. J Ayub Med Coll Abbottabad 2005;17(2):138.
16. D’Souza AL, Rajkumar C, Cooke J, et al. Probiotics in prevention of antibiotic associated diarrhoea: Meta-analysis. BMJ 2002;324:1361.
17. Cremonini F, Di Caro S, Nista EC, et al. Meta-analysis: The effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002;16:1461–7.
18. Bricker E, Garg R, Nelson R, et al. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev 2005;25(1):CD004610.
19. McFarland LV, Surawicz CM. Clostridium difficile disease: Diagnosis and treatment. In: McDonald JWD, Burroughs AK, Feagan BG, eds. Evidence based gastroenterology and hepatology, 2nd Ed. London: BMJ Books, 2004. Chapter 18: 285–301.
20. Shaw RL, Booth A, Sutton AJ, et al. Finding qualitative research: An evaluation of search strategies. BMC Med Res Methodol 2004;4:5–9.
21. Egger M, Smith GD, Phillips AN. Meta-analysis: Principles and procedures. BMJ 1997;315:1533–7.
22. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement. QUOROM Group. Br J Surg 2000;87(11):1448–54.
23. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. JAMA 2000;283:2008–12.
24. McFarland LV, Elmer GM. Properties of evidence-based probiotics for human health. In: Goklepe I, Junea V eds. Probiotics in food safety and human health: New York Marcel Dekker, Inc, 2005:109–37.
25. Surawicz CM. Antibiotic-associated diarrhoea and pseudomembranous colitis: Are they less common with poorly absorbed antimicrobials? Chemotherapy 2005;51(suppl 1):81–9.
26. Harris RP, Helfand M, Woolf SH, et al. Current methods of the U.S. Preventive Services Task Force: A review of the process. Am J Prev Med 2001;20(suppl 3):21–35.
27. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42–6.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177–88.
29. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
30. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088–101.
31. Beniwal RS, Arena V C, Thomas L, et al. A randomized trial of yogurt for prevention of antibiotic-associated diarrhoea. Dig Dis Sci 2003;48:2077–82.
32. Ahuja M, Khamar B. Antibiotic associated diarrhoea: A controlled study comparing plain antibiotic with those containing protected Lactobacillus. J Indian Med Assoc 2002;100(5):334–5.
33. Lewis S, Burmeister S, Cohen S, et al. Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005;21:469–77.
34. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhoea: A randomized, controlled study. Clin Gastroenterol Hepatol 2005;3:442–8.
35. Adam J, Barret C, Barret-Bellet A, et al. Controlled double-blind clinical trials of Ultra-Levure: Multicentre study by 25 physicians in 388 cases. Gaz Med Fr 1977;84:2072–8.
36. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii—A prospective-study. Gastroenterology 1989;96:981–8.
37. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhoea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439–48.
38. Kotowska M, Albrecht P, Szaewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: A randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005;21:583–90.
39. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998;36:171–4.
40. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: A parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002;97(11):2744–9.
41. Arvola T, Lailo K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhoea in children with respiratory infections: A randomized study. Pediatr 1999;104:64.
42. Vanderhoof JA, Whitney DB, Antonson DL, et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhoea in children. J Pediatr 1999;135:564–8.
43. Szaewska H, Kotowska M, Mrukowicz JZ, et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhoea in infants. J Pediatr 2001;138:361–5.
44. Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhoea: A randomized, placebo-controlled trial. Mayo Clin Proc 2001;76:883–9.
45. Armuzzi A, Cremonini F, Ojetti V, et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: A pilot study. Digestion 2001;63:1–7.
46. Nista EC, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: Randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2004;20:1181–8.
47. Orrhage K, Brismar B, Nord CE. Effects of supplements of Bifidobacterium longum and Lactobacillus acidophilus on the intestinal microbiota during administration of clindamycin. Microb Ecol Health Dis 1994;7:17–25.
Clostridium butyricum MIYAIRI. Pediatr Int 2003;45:86–90.

Wunderlich PF, Braun L, Fumagalli I, et al. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res 1989;17:333–8.

Borgia M, Sepe N, Brancato V, et al. A controlled clinical study on Streptococcus faecium preparation for the prevention of side reactions during long term antibiotic treatments. Curr Ther Res 1982;31:265–71.

Witsell DL, Garrett G, Yarbrough WG, et al. Effect of antibiotic-associated diarrhea with Lactobacillus sporo-

cus MRCI AIRI. Pediatr Int 2003;45:86–90.

Surawicz CM, McFarland L V, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium dif-
cile disease. JAMA 1994;271:1913–8.

LaRosa M, Bottaro G, Gulino N, et al. Prevention of antibiotic-associated diarrhea with Lactobacillus spor-
gens and fructo-oligosaccarides in children. A multicen-
tric double-blind vs placebo study. Minerva Pediatr 2003;55(5):447–52.

Jirapinyo P, Thamonsiri N, Densupsoontorn N, et al. Prevention of antibiotic-associated diarrhoea in infants by pro-
biotics. J Med Assoc Thai 2002;85(suppl 2):S739–42.

McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913–8.

Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium diffi-
cile disease: Use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012–
7.

Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000;95:S11–13.

Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: A double-blind, placebo-controlled trial. Scand J Infect Dis 2003;35:365–7.

Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005;54(Pt 9):905–6.

Plummer S, Weaver MA, Harris JC, et al. Clostridium diffi-
cile pilot study: Effects of probiotic supplementation on the incidence of Clostridium difficile diarrhoea. Int Microbiol 2004;7:59–62.